BSX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific CorporationNEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular DominanceAs of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (
NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (
NYSE:PEN), a deal that represents the company's largest M&A move in
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&AIn a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (
NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (
NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of
Wall Street’s Renaissance: Bank of America Shatters Q1 2026 Estimates as M&A and Trading Volatility SurgeThe financial landscape of 2026 has been marked by a return to high-stakes deal-making and intense market fluctuations, and no institution seems more equipped to navigate this era than Bank of America (
NYSE:BAC). On April 15, 2026, the banking giant reported a blockbuster first-quarter earnings beat, signaling a decisive
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings BeatIn a resounding display of corporate resilience, Johnson & Johnson (
NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSXNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Avanos Medical to be Acquired by American Industrial Partners for $1.27 Billion; Stock Surges 69%The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (
NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion MilestoneNEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (
NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across the board. On April 14, 2026, the healthcare titan announced it was raising its full-year 2026 revenue and earnings guidance, signaling that
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
The Great Consolidation: Q1 2026 M&A Activity Shatters Records Amid $3 Trillion Private Equity SurgeThe global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers and acquisitions. Total deal volume for the quarter reached a staggering $1.25 trillion, marking a 26% increase over
The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic BreakupDisclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (
NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSXNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health PowerhouseToday marks a definitive turning point for Hologic, Inc. (
NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony SystemST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"ST. LOUIS — April 6, 2026 — Stereotaxis (
NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Synchrony™ system. The clearance marks the final
3 of Wall Street’s Favorite Stocks for Long-Term InvestorsWall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
The Martha Transformation: A Deep Dive into Medtronic’s 2026 PivotAs of April 3, 2026, Medtronic plc (
NYSE: MDT) stands at a critical inflection point in its 77-year history. Once viewed as a lumbering healthcare conglomerate burdened by its own scale, the Dublin-based medical technology giant is currently navigating the final stages of a profound structural transformation. With the recent partial IPO of its diabetes [...]
The Great Unlocking: 2026 M&A Surge Ignites as Private Equity Confidence Hits Record 86%NEW YORK — The global mergers and acquisitions (M&A) market has entered a period of unprecedented expansion in the first half of 2026, marking a definitive end to the "deal desert" of previous years. Driven by a surge in private equity confidence—now reaching a staggering 86%—and a landmark
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and ProfitabilityThe medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (
NASDAQ:ANGO) provided the market with a compelling case study in strategic resilience. Reporting its third-quarter fiscal 2026 results, the company showcased
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming DeadlineNEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Boston Scientific Corporation (“Boston Scientific” or the “Company”) (
NYSE: BSX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options
